Mitoxantrone, l-leucovorin and 5-fluorouracil

An effective and well tolerated first-line treatment for advanced breast cancer

Vito Lorusso, Sergio Mancarella, Annamaria Catino, Mario Brandi, Angelo Paradiso, Agnese Latorre, Antonella Mastria, Alessandra De Mitrio, Michele Guida, Mario De Lena

Research output: Contribution to journalArticle

Abstract

Aims and background: The combination of mitoxantrone plus leucovorin/fluorouracil in heavily pretreated patients with advanced breast cancer has shown significant activity and extremely good tolerability. The aim of this study was to evaluate the activity of this combination in patients not previously submitted to chemotherapy. Methods: From May 1993 to December 1995 we treated 80 patients with advanced breast cancer with a combination of mitoxantrone, l-leucovorin and 5-fluorouracil. All patients had histologically or cytologically proven breast cancer, WHO performance status 0-3, normal hematological parameters and normal serum bilirubin. Prior chemotherapy for metastatic disease was not allowed, whereas adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or adjuvant anthracycline (doxorubicin or epirubicin) therapy was allowed; a single prior hormone treatment was permitted. Chemotherapy consisted of mitoxantrone 12 mg/m2 i.v. day 1, l-leucovorin 150 mg/m2 i.v. days 1, 2 and 3 and 5-fluorouracil 350 mg/m2 i.v. days 1, 2 and 3. The courses were repeated every 3 weeks. Results: Objective response (CR + PR) was observed in 46/80 (57%) patients (95% CI, 46%-68%). Complete response (CR) was observed in 21/80 cases (26%). Response was observed in 14/24 (58%) patients with soft tissues as the dominant site of disease, in 22/34 (65%) patients with visceral involvement and in 10/22 (45%) of those with bone as the dominant site of disease. The median duration of response and survival was 9 months (range, 3-16) and 22 months (range, 2-48+), respectively. Toxicity was very manageable, with grade 4 leukopenia and thrombocytopenia in 6/80 (7.5%) and 1/80 (1.25%) patients, respectively, and negligible non-hematological toxicity. Conclusions: The combination of mitoxantrone, 5-fluorouracil and high-dose l-leucovorin is a safe and effective regimen for first-line treatment of advanced breast cancer.

Original languageEnglish
Pages (from-to)60-64
Number of pages5
JournalTumori
Volume85
Issue number1
Publication statusPublished - Jan 1999

Fingerprint

Mitoxantrone
Leucovorin
Fluorouracil
Breast Neoplasms
Therapeutics
Drug Therapy
Epirubicin
Anthracyclines
Leukopenia
Bilirubin
Methotrexate
Doxorubicin
Cyclophosphamide
Hormones
Bone and Bones
Survival

Keywords

  • Breast cancer
  • Chemotherapy
  • Mitoxantrone

ASJC Scopus subject areas

  • Cancer Research

Cite this

Mitoxantrone, l-leucovorin and 5-fluorouracil : An effective and well tolerated first-line treatment for advanced breast cancer. / Lorusso, Vito; Mancarella, Sergio; Catino, Annamaria; Brandi, Mario; Paradiso, Angelo; Latorre, Agnese; Mastria, Antonella; De Mitrio, Alessandra; Guida, Michele; De Lena, Mario.

In: Tumori, Vol. 85, No. 1, 01.1999, p. 60-64.

Research output: Contribution to journalArticle

@article{4287057e0a9541ea8a6f507043828e74,
title = "Mitoxantrone, l-leucovorin and 5-fluorouracil: An effective and well tolerated first-line treatment for advanced breast cancer",
abstract = "Aims and background: The combination of mitoxantrone plus leucovorin/fluorouracil in heavily pretreated patients with advanced breast cancer has shown significant activity and extremely good tolerability. The aim of this study was to evaluate the activity of this combination in patients not previously submitted to chemotherapy. Methods: From May 1993 to December 1995 we treated 80 patients with advanced breast cancer with a combination of mitoxantrone, l-leucovorin and 5-fluorouracil. All patients had histologically or cytologically proven breast cancer, WHO performance status 0-3, normal hematological parameters and normal serum bilirubin. Prior chemotherapy for metastatic disease was not allowed, whereas adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or adjuvant anthracycline (doxorubicin or epirubicin) therapy was allowed; a single prior hormone treatment was permitted. Chemotherapy consisted of mitoxantrone 12 mg/m2 i.v. day 1, l-leucovorin 150 mg/m2 i.v. days 1, 2 and 3 and 5-fluorouracil 350 mg/m2 i.v. days 1, 2 and 3. The courses were repeated every 3 weeks. Results: Objective response (CR + PR) was observed in 46/80 (57{\%}) patients (95{\%} CI, 46{\%}-68{\%}). Complete response (CR) was observed in 21/80 cases (26{\%}). Response was observed in 14/24 (58{\%}) patients with soft tissues as the dominant site of disease, in 22/34 (65{\%}) patients with visceral involvement and in 10/22 (45{\%}) of those with bone as the dominant site of disease. The median duration of response and survival was 9 months (range, 3-16) and 22 months (range, 2-48+), respectively. Toxicity was very manageable, with grade 4 leukopenia and thrombocytopenia in 6/80 (7.5{\%}) and 1/80 (1.25{\%}) patients, respectively, and negligible non-hematological toxicity. Conclusions: The combination of mitoxantrone, 5-fluorouracil and high-dose l-leucovorin is a safe and effective regimen for first-line treatment of advanced breast cancer.",
keywords = "Breast cancer, Chemotherapy, Mitoxantrone",
author = "Vito Lorusso and Sergio Mancarella and Annamaria Catino and Mario Brandi and Angelo Paradiso and Agnese Latorre and Antonella Mastria and {De Mitrio}, Alessandra and Michele Guida and {De Lena}, Mario",
year = "1999",
month = "1",
language = "English",
volume = "85",
pages = "60--64",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Mitoxantrone, l-leucovorin and 5-fluorouracil

T2 - An effective and well tolerated first-line treatment for advanced breast cancer

AU - Lorusso, Vito

AU - Mancarella, Sergio

AU - Catino, Annamaria

AU - Brandi, Mario

AU - Paradiso, Angelo

AU - Latorre, Agnese

AU - Mastria, Antonella

AU - De Mitrio, Alessandra

AU - Guida, Michele

AU - De Lena, Mario

PY - 1999/1

Y1 - 1999/1

N2 - Aims and background: The combination of mitoxantrone plus leucovorin/fluorouracil in heavily pretreated patients with advanced breast cancer has shown significant activity and extremely good tolerability. The aim of this study was to evaluate the activity of this combination in patients not previously submitted to chemotherapy. Methods: From May 1993 to December 1995 we treated 80 patients with advanced breast cancer with a combination of mitoxantrone, l-leucovorin and 5-fluorouracil. All patients had histologically or cytologically proven breast cancer, WHO performance status 0-3, normal hematological parameters and normal serum bilirubin. Prior chemotherapy for metastatic disease was not allowed, whereas adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or adjuvant anthracycline (doxorubicin or epirubicin) therapy was allowed; a single prior hormone treatment was permitted. Chemotherapy consisted of mitoxantrone 12 mg/m2 i.v. day 1, l-leucovorin 150 mg/m2 i.v. days 1, 2 and 3 and 5-fluorouracil 350 mg/m2 i.v. days 1, 2 and 3. The courses were repeated every 3 weeks. Results: Objective response (CR + PR) was observed in 46/80 (57%) patients (95% CI, 46%-68%). Complete response (CR) was observed in 21/80 cases (26%). Response was observed in 14/24 (58%) patients with soft tissues as the dominant site of disease, in 22/34 (65%) patients with visceral involvement and in 10/22 (45%) of those with bone as the dominant site of disease. The median duration of response and survival was 9 months (range, 3-16) and 22 months (range, 2-48+), respectively. Toxicity was very manageable, with grade 4 leukopenia and thrombocytopenia in 6/80 (7.5%) and 1/80 (1.25%) patients, respectively, and negligible non-hematological toxicity. Conclusions: The combination of mitoxantrone, 5-fluorouracil and high-dose l-leucovorin is a safe and effective regimen for first-line treatment of advanced breast cancer.

AB - Aims and background: The combination of mitoxantrone plus leucovorin/fluorouracil in heavily pretreated patients with advanced breast cancer has shown significant activity and extremely good tolerability. The aim of this study was to evaluate the activity of this combination in patients not previously submitted to chemotherapy. Methods: From May 1993 to December 1995 we treated 80 patients with advanced breast cancer with a combination of mitoxantrone, l-leucovorin and 5-fluorouracil. All patients had histologically or cytologically proven breast cancer, WHO performance status 0-3, normal hematological parameters and normal serum bilirubin. Prior chemotherapy for metastatic disease was not allowed, whereas adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or adjuvant anthracycline (doxorubicin or epirubicin) therapy was allowed; a single prior hormone treatment was permitted. Chemotherapy consisted of mitoxantrone 12 mg/m2 i.v. day 1, l-leucovorin 150 mg/m2 i.v. days 1, 2 and 3 and 5-fluorouracil 350 mg/m2 i.v. days 1, 2 and 3. The courses were repeated every 3 weeks. Results: Objective response (CR + PR) was observed in 46/80 (57%) patients (95% CI, 46%-68%). Complete response (CR) was observed in 21/80 cases (26%). Response was observed in 14/24 (58%) patients with soft tissues as the dominant site of disease, in 22/34 (65%) patients with visceral involvement and in 10/22 (45%) of those with bone as the dominant site of disease. The median duration of response and survival was 9 months (range, 3-16) and 22 months (range, 2-48+), respectively. Toxicity was very manageable, with grade 4 leukopenia and thrombocytopenia in 6/80 (7.5%) and 1/80 (1.25%) patients, respectively, and negligible non-hematological toxicity. Conclusions: The combination of mitoxantrone, 5-fluorouracil and high-dose l-leucovorin is a safe and effective regimen for first-line treatment of advanced breast cancer.

KW - Breast cancer

KW - Chemotherapy

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=0033044741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033044741&partnerID=8YFLogxK

M3 - Article

VL - 85

SP - 60

EP - 64

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -